论文部分内容阅读
目的探讨性研究晚期胃癌的姑息性联合化疗方案。方法自1992年3月至1996年12月，我们采用丝裂霉素（MMC）、5-氟脲嘧啶（5－Fu）和顺铂（DDP）联合化疗方案治疗晚期胃癌35例。结果近期总有效率（CR＋PR）为68．57％，其中CR8．57％，PR60％；中位生存时间（MST）13．5月；1、2、3、5年生存率分别为82．75％、22．85％、7．62％和7．62％。消化道反应和骨髓抑制轻微，但有一定的心脏毒性反应和相关感染发生。结论本MFP方案疗效较满意，毒副反应轻，建议在晚期胃癌患者中应用，尤以低分化腺癌者较为适用。
Objective To investigate the palliative combined chemotherapy for advanced gastric cancer. Methods From March 1992 to December 1996, we used mitomycin (MMC), 5-fluorouracil (5-Fu) and cisplatin (DDP) combined chemotherapy regimens for the treatment of 35 cases of advanced gastric cancer. Results The total effective rate (CR+PR) was 68.57% in the near future, including CR 8.57% and PR 60%; the median survival time (MST) was 13.5 months; the survival rates at 1, 2, 3, and 5 years were 82.75 respectively. %, 22.85%, 7.62% and 7.62%. Gastrointestinal reaction and myelosuppression are mild, but there is a certain cardiotoxicity and related infections. Conclusion The efficacy of the MFP program is satisfactory, with mild side effects. It is recommended that it be used in patients with advanced gastric cancer, especially those with poorly differentiated adenocarcinoma.